Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443464 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL5029670 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134708 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL182764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL9291634 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4391706 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8940690 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL258033 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4912663 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6635746-B1 | Extracting elementary bodies of Chlamydia with detergent and reducing agent to dissolve cytoplasmic material, separating outer membrane material, extracting with nonionic detergents and reducing agent, separating outer membrane antigen extract | AVENTIS PASTEUR LIMITED (CA) | 2003-10-21 | — | — | US | claimed |
| US-5286625-A | Pretreatment with nitric acid and surfactant | SEIKAGAKU CORPORATION (JP) | 1994-02-15 | — | — | US | claimed |
| US-10548860-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190192452-A1 | HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-10220009-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150196512-A1 | HIF-1 Modulator Paint Formulation and Uses Thereof | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| WO-2014036414-A2 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| US-8137975-B2 | Method for a rapid antibody-based analysis of platelet populations | BECKMAN COULTER, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2215219-A1 | METHOD FOR A RAPID ANTIBODY-BASED ANALYSIS OF PLATELET POPULATIONS | Beckman Coulter, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7674598-B2 | Method for a fully automated monoclonal antibody-based extended differential | BECKMAN COULTER, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1294422-B1 | Medical System for Reducing Vascular Occlusions | CORDIS CORP (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20030104073-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORDIS US CORP | 2003-06-05 | — | — | US | disclosed |
| EP-1294422-A1 | METHODS AND SYSTEMS FOR ENHANCING FLUID FLOW THROUGH AN OBSTRUCTED VASCULAR SITE | Corazon Technologies, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6533767-B2 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORAZON TECHNOLOGIES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-6488671-B1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORAZON TECHNOLOGIES, INC. | 2002-12-03 | — | — | US | disclosed |
| US-6451739-B1 | ACTIVE QUATERNARY AMMONIUM COMPOUND CONCENTRATES SUCH AS MEPIQUAT OR CHLORMEQUAT AND AT LEAST ONE AUXILIARY SELECTED FROM ALKYLGLUCOSIDES, AND ALKYLSULFONATES OR ALKYLARYLSULFONATES | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
| US-20010039411-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CORDIS US CORP | 2001-11-08 | — | — | US | disclosed |
| WO-2001070320-A1 | METHODS AND SYSTEMS FOR ENHANCING FLUID FLOW THROUGH AN OBSTRUCTED VASCULAR SITE | CORAZON TECHNOLOGIES, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1100329-A1 | AQUEOUS GROWTH-REGULATING COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000007445-A1 | AQUEOUS GROWTH-REGULATING COMPOSITIONS | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104073-A1 | Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same | CA2, DUOX2, SMOX | GBA1 896/4885SLC2A1 225/4885MAPK1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.